Share on LinkedInShare on LinkedIn

ARTICLE · 22 NOVEMBER 2017

The Patent Office provides clarity regarding enablement of polypeptide claims

Patent office stringently applies new support laws which set higher thresholds required in a patent specification.

AustraliaIntellectual Property

Australia has relatively recently implemented support laws that require a specification to provide sufficient information to enable the skilled person to perform an invention over the entire scope of the claims without undue burden or the need for further invention. These new support laws have been stringently applied by the Patent Office, in particular in relation to claims defining chemical compounds, such as proteins where, in many cases, the only claims considered to be enabled are ones directed to embodiments exemplified in the specification.

In Evolva SA [2017] APO 57 (14 November 2017) the Patent Office considered the enablement of claims directed to polypeptide sequences covered by at least 90% sequence identity to defined polypeptide sequences.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from